Inventiva (IVA) Net Margin (2020 - 2021)
Inventiva's (IVA) quarterly Net Margin came in at 15249.23% in Q2 2021, down 335193.0% year-on-year from N/an in Q2 2020, and down 159.83% quarter-over-quarter from 5868.92% in Q1 2021.
Inventiva (IVA) Net Margin (2020 - 2021) Analysis & Trends
Inventiva's Net Margin history runs 2 years deep, the most recent figure standing at 15249.23% for Q2 2021.
- On a quarterly basis, Net Margin fell 335193.0% year-over-year to 15249.23% in Q2 2021; TTM through Jun 2021 was 18054.76%, a N/A change from a year earlier, with the FY2025 full-year figure at 7892.26%, down 788753.0% from the prior year.
- Net Margin retreated to 15249.23% in Q2 2021 per IVA's latest filing, from 5868.92% in the prior quarter.
- Across five years, Net Margin topped out at 5868.92% in Q1 2021 and bottomed at 15249.23% in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -15,249.23% |
| Mar 31, 2021 | -5,868.92% |
| Jun 30, 2020 | -11,897.30% |
| Mar 31, 2020 | -7,783.91% |